Daily Endocrinology Research Analysis
Long-acting GLP-1 receptor agonists consistently reduce major cardiovascular events, heart failure hospitalization, kidney outcomes, and all-cause mortality in type 2 diabetes, with benefits extending to oral semaglutide and irrespective of SGLT2 inhibitor use. An updated meta-analysis of anti-CD3 monoclonal antibodies in type 1 diabetes confirms preserved C-peptide and reduced insulin needs, highlighting dose and early initiation as key effect modifiers.
Summary
Long-acting GLP-1 receptor agonists consistently reduce major cardiovascular events, heart failure hospitalization, kidney outcomes, and all-cause mortality in type 2 diabetes, with benefits extending to oral semaglutide and irrespective of SGLT2 inhibitor use. An updated meta-analysis of anti-CD3 monoclonal antibodies in type 1 diabetes confirms preserved C-peptide and reduced insulin needs, highlighting dose and early initiation as key effect modifiers.
Research Themes
- Cardiorenal protection with incretin-based therapies
- Combination therapy strategies in type 2 diabetes (GLP-1RA plus SGLT2i)
- Immunomodulation to preserve beta-cell function in type 1 diabetes
Selected Articles
1. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.
Across 10 randomized outcomes trials (n=71,351), long-acting GLP-1RAs reduced MACE by 14%, HHF by 14%, composite kidney events by 17%, and all-cause mortality by 12%, with consistent benefits for injectable and oral formulations. No excess risks of severe hypoglycemia, retinopathy, or pancreatic events were observed.
Impact: Provides definitive class-level evidence, including oral semaglutide, for broad cardiorenal and mortality benefits of long-acting GLP-1RAs in T2D. Clarifies route-independence and safety, directly informing guidelines and therapeutic selection.
Clinical Implications: Use long-acting GLP-1RAs for cardiorenal risk reduction in T2D irrespective of administration route; consider combining with SGLT2 inhibitors. Reassure patients about no increased risks of severe hypoglycemia, retinopathy, or pancreatic events.
Key Findings
- Reduced MACE by 14% (HR 0.86; 95% CI 0.81–0.90) across 10 trials (n=71,351).
- Reduced hospitalization for heart failure by 14% (HR 0.86; 95% CI 0.79–0.93) and composite kidney outcome by 17% (HR 0.83; 95% CI 0.75–0.92).
- Benefits were consistent across subcutaneous and oral GLP-1RA formulations with no heterogeneity by route.
- No increased risks of severe hypoglycemia, retinopathy, or pancreatic events were detected.
Methodological Strengths
- Trial-level meta-analysis of randomized, placebo-controlled cardiovascular and kidney outcome trials.
- Inclusion of recent large trials (SOUL, FLOW) and use of random-effects models with heterogeneity assessment.
Limitations
- Trial-level meta-analysis limits detailed subgroup analyses and may introduce ecological bias.
- Variations in trial design, populations, and outcome definitions across included studies.
Future Directions: Individual participant data meta-analyses to refine subgroup effects; pragmatic trials to evaluate combination strategies with SGLT2i and real-world effectiveness across diverse populations.
BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce the incidence of major adverse cardiovascular events (MACE) in type 2 diabetes (T2D), although whether benefits extend to both subcutaneous and oral formulations remains unclear. PURPOSE: In these meta-analyses, including new data from the Semaglutide cardiOvascular oUtcomes triaL (SOUL) (oral semaglutide) and Evaluate Renal Function with Semaglutide Once Weekly (FLOW) trial, we examined cardiovascular (CV) and kidney benefits and risks of long-acting (defined as having pharmacokinetics sufficient to provide 24-h activity) GLP-1RA in T2D. DATA SOURCES: A systematic review of PubMed was conducted (to 7 February 2025). STUDY SELECTION: Randomized placebo-controlled CV and kidney outcomes trials of GLP-1RA with ≥500 individuals with T2D were included. DATA EXTRACTION: A random-effects model was used to estimate hazard ratios (HRs) for MACE, its components, all-cause mortality, hospitalization for heart failure (HHF), a composite kidney outcome (kidney failure [kidney replacement therapy or persistent estimated glomerular filtration rate [eGFR] <15 mL/min/1.73 m2], sustained ≥50% eGFR decline or nearest equivalent, or kidney-related death), worsening kidney function, and safety outcomes. DATA SYNTHESIS: Across 10 trials (n = 71,351), long-acting GLP-1RA reduced incidence rate of MACE by 14% (HR 0.86 [95% CI 0.81, 0.90]; I2 = 27.6%), HHF by 14% (0.86 [0.79, 0.93]; I2 = 2.1%), and the composite kidney outcome by 17% (0.83 [0.75, 0.92]; I2 = 20.4%) and all-cause mortality by 12% (0.88 [0.82, 0.93]; I2 = 17.5%). A consistent 14% reduction was seen for all MACE components. There was no significant heterogeneity by GLP-1RA administration route (subcutaneous vs. oral). There were no increased risks of severe hypoglycemia, retinopathy, or pancreatic events. LIMITATIONS: Trial-level meta-analyses preclude detailed subgroup analyses and may introduce ecological bias. CONCLUSIONS: As a group, long-acting GLP-1RA, including both injectable and oral formulations, reduce incidence of MACE, HHF, and kidney events and all-cause mortality in T2D.
2. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
In SOUL, oral semaglutide reduced MACE by 14% overall (HR 0.86; 95% CI 0.77–0.96). Benefits were consistent among participants with or without SGLT2 inhibitor therapy at baseline or during follow-up, and serious adverse events were similar, supporting the safety of combination therapy.
Impact: Addresses the clinical question of combining GLP-1RA with SGLT2i, showing route-agnostic CV benefit and safety of oral semaglutide regardless of SGLT2i use. This informs real-world optimization of cardioprotective regimens.
Clinical Implications: For T2D with ASCVD/CKD, oral semaglutide can be added to SGLT2i without compromising safety and with preserved CV benefit. Consider combination therapy to maximize cardiorenal protection.
Key Findings
- Overall MACE reduction with oral semaglutide vs placebo: HR 0.86 (95% CI 0.77–0.96).
- Effect estimates were similar with baseline SGLT2i use (HR 0.89; 95% CI 0.71–1.11) and without (HR 0.84; 95% CI 0.74–0.95); no signal of harm with combination.
- Serious adverse events were comparable between groups, supporting safety of co-administration.
Methodological Strengths
- Prespecified subgroup analyses within a large, randomized, placebo-controlled outcomes trial.
- Long follow-up (mean ~47.5 months) with adjudicated MACE and systematic safety assessment.
Limitations
- Subgroup analyses may be underpowered; confidence intervals in SGLT2i users crossed 1.0.
- Not designed to detect interaction effects definitively; background therapies may vary over time.
Future Directions: Direct randomized trials testing combination therapy strategies (GLP-1RA plus SGLT2i) with renal and HF endpoints; mechanistic studies to delineate additive vs. independent pathways.
BACKGROUND: Both GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT2 (sodium-glucose cotransporter-2) inhibitors (SGLT2i) improve cardiovascular outcomes in people with type 2 diabetes and cardiovascular or chronic kidney disease. However, there are limited data about the effect of combining these agents on cardiovascular and safety outcomes. METHODS: The SOUL trial (Semaglutide Cardiovascular Outcomes Trial; NCT03914326) randomized 9650 participants with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease to oral semaglutide or placebo. As prespecified, participants were analyzed according to baseline use of SGLT2i (yes, n=2596; no, n=7054), and subsequently for any use of SGLT2i during the trial (yes, n=4718; no, n=4932). The primary outcome was time to first major adverse cardiovascular event, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Safety was evaluated by comparing the incidence of serious adverse events. RESULTS: Over a mean follow-up of 47.5±10.9 months, the risk of the primary outcome in the overall trial population was 14% lower for oral semaglutide versus placebo (hazard ratio, 0.86; 95% CI, 0.77-0.96). In those taking SGLT2i at baseline, there were 143 of 1296 (semaglutide) versus 158 of 1300 (placebo) primary outcome events (hazard ratio, 0.89; 95% CI, 0.71-1.11); and 436 of 3529 versus 510 of 3525, respectively, in participants not taking SGLT2i at baseline (hazard ratio, 0.84; 95% CI, 0.74-0.95; CONCLUSIONS: Oral semaglutide reduced major adverse cardiovascular event outcomes independently of concomitant SGLT2i treatment, and this combination appeared to be safe. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03914326.
3. Anti-CD3 monoclonal antibody in treating patients with type 1 diabetes: an updated systematic review and meta-analysis.
Across 11 RCTs (n=1,573), anti-CD3 mAbs preserved beta-cell function (increased C-peptide AUC) and reduced daily insulin needs. Greater benefits were observed with higher cumulative dose (≥25 mg), earlier initiation (≤6 weeks post-diagnosis), and in younger patients; dose emerged as the dominant modifier.
Impact: Consolidates randomized evidence for anti-CD3 therapy in T1D and identifies dose and timing as critical drivers of efficacy, informing clinical deployment and trial design.
Clinical Implications: Consider early initiation of anti-CD3 therapy soon after T1D diagnosis, aiming for adequate cumulative dosing, particularly in younger patients. Most adverse events are transient and manageable.
Key Findings
- Anti-CD3 mAbs increased C-peptide AUC (SMD 0.337; 95% CI 0.105–0.569) and reduced daily insulin requirement (SMD −0.598; 95% CI −0.927 to −0.269).
- Stronger efficacy with higher cumulative dose (≥25 mg), earlier initiation (≤6 weeks post-diagnosis), and age ≤18 years.
- Meta-regression identified cumulative dose as the dominant modifier, attenuating effects of age and time from diagnosis.
- Most adverse events were transient and medically manageable.
Methodological Strengths
- Randomized controlled trials only, with meta-regression and prespecified subgroup analyses.
- Multiple clinically relevant endpoints (C-peptide AUC, insulin requirement) with consistent direction of effect.
Limitations
- Use of standardized mean differences may limit direct clinical interpretability across assays.
- Heterogeneity in specific anti-CD3 agents, dosing regimens, and follow-up durations; long-term outcomes remain uncertain.
Future Directions: Head-to-head trials optimizing dosing and timing; evaluation of long-term clinical outcomes (hypoglycemia, complications), and combination strategies with other disease-modifying agents.
OBJECTIVE: To evaluate the efficacy of anti-CD3 monoclonal antibody (mAb) in patients with type 1 diabetes (T1D) and identify the influencing factors. METHODS: Randomized controlled trials comparing anti-CD3 mAb with placebo or standard care in T1D participants were screened from PubMed, Embase, and Cochrane databases until 31 May 2024. Changes in area under the curve (AUC) of C-peptide, HbA1c level and daily insulin requirement were main outcomes. Results were computed as standardized mean difference (SMD) and 95% confidence interval (CI). Meta-regression and subgroup analyses were also performed. RESULTS: Eleven eligible trials involving 1573 T1D participants were included in this meta-analysis. Compared with control group, anti-CD3 mAb significantly increased AUC of C-peptide (SMD = 0.337, 95% CI 0.105 to 0.569, P = 0.004) and decreased daily insulin requirement (SMD = - 0.598, 95% CI - 0.927 to - 0.269, P < 0.001). Subgroup analysis revealed that low average age (≤ 18 years old: SMD = 0.546, 95% CI 0.203 to 0.889, P < 0.001), high cumulative dose of anti-CD3 mAb (≥ 25 mg: SMD = 0.588, 95% CI 0.424 to 0.752, P < 0.001), and short T1D diagnosis duration before enrollment (≤ 6 weeks: SMD = 0.609, 95% CI 0.405 to 0.814, P < 0.001) were significantly associated with an increase in AUC of C-peptide. Notably, meta-regression analysis revealed that cumulative dose was the most critical factor, masking the effect of average age and T1D diagnosis duration. Most adverse events were transient and could be medically treated. CONCLUSION: Anti-CD3 mAb effectively preserves C-peptide secretion and reduces insulin requirement in patients with T1D. Younger age (≤ 18 years), earlier treatment initiation (≤ 6 weeks post-diagnosis), higher cumulative doses (≥ 25 mg) may present better therapeutic effect.